<link file:2166 _blank pdf "Initiates file download">Press release</link>

Fresenius Medical Care, the world’s largest provider of dialysis products and services, has launched a new cycler that delivers a Peritoneal Dialysis (PD) therapy tailored to individual patients’ needs. sleep•safe harmony was presented to leading specialists from around the world at two scientific congresses in Berlin and Madrid on September 6 and 7. The device is available from now on in selected countries including Germany, Spain, Great Britain and France.

Dialysis patients have chronic kidney disease in common, but they still differ in many ways – by age, height, weight, stage of illness and residual renal function, etc. All these differences have a decisive impact on the required treatment. If the treatment is closely tailored to the needs of the individual patient, the patent’s overall feeling of health and well-being is increased. Compared with previous models, sleep•safe harmony is even easier to operate, and makes it possible for more patients to tailor their own treatments. PD is a therapy that can be conducted at home, if the patient meets certain medical conditions and is willing to learn how to perform the treatment. 

sleep•safe harmony has animations built into the machine’s screen that guide the patient through the procedure, so that the patient is assured that all the treatment steps are being performed as planned. This contributes to the improvement of patient compliance and saves training time. Thereby, the new device strongly supports patients in performing their treatment on their own.

Specifically, Adapted APD (Automated PD) therapy with sleep•safe harmony enables physicians and nurses to combine sequences of short dwells and small fill volumes with long dwells and large fill volumes and varying glucose concentrations. Adapted APD is a new way of prescribing PD that optimizes ultrafiltration and clearance within one PD session. sleep•safe harmony enables complete individualization for a fully personalized treatment, as well as guided prescription on the cycler or via PatientOnLine software.

Moreover, all therapies carried out with sleep•safe harmony are supported by the innovative Fresenius Medical Care FlexPoint technology. By controlling various settings, this technology helps to achieve optimized treatment efficiency, keep treatment within the prescribed time, and minimize potential alarms while benefiting the patient’s well-being and security by avoiding overfilling.

In addition, the sleep•safe harmony cycler offers advanced features aimed at improving patient care. The device’s key features are: a large touch screen with animations guiding through each treatment step; guided prescriptions directly on the device; optimized fluid usage (no extra volume for priming needed); convenient handling through automatic connection and barcode recognition of fluid bags, integrated handles and PatientCardPlus with more than 12 months capacity of treatment data, and simple installation via plug & use – due to double insulation, no transformer is needed.

For more information, visit <link www.sleepsafe-harmony.com _blank externlink>www.sleepsafe-harmony.com</link>.

Note to the media: Images of the product sleep•safe harmony can be found <link www.fresenius.com/5058_5572.htm _blank externlink Images>here</link>.

***

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,335 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 280,942 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

***